HUP0200859A2 - Cikloalkil-szubsztituált benzimidazolok, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk - Google Patents

Cikloalkil-szubsztituált benzimidazolok, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk

Info

Publication number
HUP0200859A2
HUP0200859A2 HU0200859A HUP0200859A HUP0200859A2 HU P0200859 A2 HUP0200859 A2 HU P0200859A2 HU 0200859 A HU0200859 A HU 0200859A HU P0200859 A HUP0200859 A HU P0200859A HU P0200859 A2 HUP0200859 A2 HU P0200859A2
Authority
HU
Hungary
Prior art keywords
compounds
group
cyclo
preparation
pharmaceutical compositions
Prior art date
Application number
HU0200859A
Other languages
English (en)
Inventor
Roland Grandel
Thomas Hörger
Michael Kock
Wilfried Lubisch
Reinhold Müller
Sabine Schult
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0200859A2 publication Critical patent/HUP0200859A2/hu
Publication of HUP0200859A3 publication Critical patent/HUP0200859A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Abstract

A találmány tárgyát az általános képletű vegyületek - ahol A telítettvagy egyszeresen telítetlen karbociklus, amely 3-8 szénatomból áll, éstartalmazhat egy adott esetben diszubsztituált kondenzáltbenzolgyűrűt; R1 hidrogén-, halogénatom, alkil-, hidroxi-, nitro-,trifluor-metil-, cianocsoport, -NR11R12, -NH-CO-R13 általános képletűcsoport, alkoxi-csoport; és R2 hidrogénatom, alkil- vagy alkil-fenil-csoport és tautomereik, enantiomereik és diasztereomereik, lehetségescisz-transz izomereik és prodrugjaik, valamint alkalmazásuk képezik. Atalálmány szerinti vegyületek a poli(ADP-ribóz)-polimeráz (PARP) vagypoli(ADP-ribóz)-szintáz (PARS) inhibitorai. A találmány kiterjed avegyületek előállítására és a vegyületeket tartalmazógyógyszerkészítményekre is. Ó
HU0200859A 1999-04-22 2000-04-11 Cyclo-alkyl substituted benzimidazoles, pharmaceutical compositions containing them, their preparation and their use HUP0200859A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19918211A DE19918211A1 (de) 1999-04-22 1999-04-22 Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung

Publications (2)

Publication Number Publication Date
HUP0200859A2 true HUP0200859A2 (hu) 2002-11-28
HUP0200859A3 HUP0200859A3 (en) 2002-12-28

Family

ID=7905444

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200859A HUP0200859A3 (en) 1999-04-22 2000-04-11 Cyclo-alkyl substituted benzimidazoles, pharmaceutical compositions containing them, their preparation and their use

Country Status (27)

Country Link
US (1) US6737421B1 (hu)
EP (1) EP1171424B1 (hu)
JP (1) JP4002067B2 (hu)
KR (1) KR20020002435A (hu)
CN (1) CN1349510A (hu)
AR (1) AR023754A1 (hu)
AT (1) ATE432264T1 (hu)
AU (1) AU3965900A (hu)
BG (1) BG65513B1 (hu)
BR (1) BR0009948A (hu)
CA (1) CA2371174C (hu)
CO (1) CO5170500A1 (hu)
CZ (1) CZ20013775A3 (hu)
DE (2) DE19918211A1 (hu)
ES (1) ES2325674T3 (hu)
HK (1) HK1045513A1 (hu)
HU (1) HUP0200859A3 (hu)
IL (1) IL145882A0 (hu)
NO (1) NO20014963L (hu)
NZ (1) NZ514930A (hu)
PL (1) PL198919B1 (hu)
RU (1) RU2001131550A (hu)
SK (1) SK15222001A3 (hu)
TR (1) TR200103047T2 (hu)
TW (1) TWI278452B (hu)
WO (1) WO2000064878A1 (hu)
ZA (1) ZA200108204B (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0208010A (pt) 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
EP1527183B1 (de) 2002-07-26 2008-08-20 BASF Plant Science GmbH Neue selektionsverfahren
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
CA2500888C (en) 2002-10-01 2010-07-13 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
CA2507027C (en) 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CN101137752B (zh) 2005-03-08 2013-04-03 巴斯福植物科学有限公司 增强表达的内含子序列
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CA2623822C (en) 2005-09-29 2013-11-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
JP5162465B2 (ja) * 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である
AU2007232297B2 (en) * 2006-04-03 2012-09-20 Msd Italia S.R.L. Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
CA2647373C (en) * 2006-05-02 2014-03-18 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US20090062268A1 (en) * 2007-08-27 2009-03-05 Lead Therapeutics, Inc. Novel inhibitors of poly(adp-ribose)polymerase (parp)
KR101653548B1 (ko) * 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
ATE547707T1 (de) * 2008-05-16 2012-03-15 Cellzome Ag Verfahren zur identifizierung von mit parp wechselwirkenden molekülen und zur aufreinigung von parp-proteinen
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
JP5944320B2 (ja) 2009-11-27 2016-07-05 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー 最適化エンドヌクレアーゼおよびその使用
DE112010004583T5 (de) 2009-11-27 2012-10-18 Basf Plant Science Company Gmbh Chimäre Endonukleasen und Anwendungen davon
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
EP2569307A2 (en) 2010-05-10 2013-03-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
RU2476224C2 (ru) * 2010-11-12 2013-02-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Российской академии медицинских наук (ФГБУ "НИИ фармакологии имени В.В. Закусова" РАМН) Лекарственное средство с кардиопротективной активностью
EP2736896B1 (en) * 2011-07-26 2016-12-14 Nerviano Medical Sciences S.r.l. 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
US20140311979A1 (en) 2011-11-17 2014-10-23 Alexander Schluttig Device and Method for Producing Sterile Water by Means of a Cross-Flow Liquid Sterile Filter
US9365576B2 (en) * 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
DE102015006278B4 (de) 2015-05-15 2021-09-09 Alexander Schluttig Selbstdesinfizierender Geruchsverschluss
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020233676A1 (en) * 2019-05-22 2020-11-26 Beigene, Ltd. Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2649125B1 (de) 1976-10-28 1978-01-12 Baelz Gmbh Helmut Warmwasserheizungs- oder -bereitungsanlage mi regelbarer Strahlpumpe
GR65025B (en) 1977-07-21 1980-06-16 Thomae Gmbh Dr K Method for the preparation of new imidazo-isokinolin-diones
DE2732951A1 (de) 1977-07-21 1979-02-08 Thomae Gmbh Dr K Neue imidazo-isochinolin-dione
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3545652A1 (de) 1985-12-21 1987-06-25 Daimler Benz Ag Einrichtung zur vortriebsregelung an kraftfahrzeugen
DE3546575A1 (de) 1985-12-21 1987-10-01 Daimler Benz Ag Einrichtung zur vortriebsregelung an kraftfahrzeugen
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
KR950704228A (ko) 1992-12-02 1995-11-17 알렌 제이. 스피겔 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors)
ATE225173T1 (de) 1995-08-02 2002-10-15 Univ Newcastle Ventures Ltd Benzimidazol verbindungen
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds

Also Published As

Publication number Publication date
EP1171424A1 (de) 2002-01-16
AR023754A1 (es) 2002-09-04
RU2001131550A (ru) 2004-02-27
KR20020002435A (ko) 2002-01-09
NO20014963D0 (no) 2001-10-12
BR0009948A (pt) 2002-01-08
WO2000064878A1 (de) 2000-11-02
HUP0200859A3 (en) 2002-12-28
JP2002543066A (ja) 2002-12-17
US6737421B1 (en) 2004-05-18
CA2371174A1 (en) 2000-11-02
ATE432264T1 (de) 2009-06-15
TWI278452B (en) 2007-04-11
TR200103047T2 (tr) 2002-05-21
PL198919B1 (pl) 2008-07-31
BG105993A (en) 2002-05-31
CA2371174C (en) 2007-02-20
NO20014963L (no) 2001-11-13
BG65513B1 (bg) 2008-10-31
AU3965900A (en) 2000-11-10
JP4002067B2 (ja) 2007-10-31
SK15222001A3 (sk) 2002-06-04
PL351557A1 (en) 2003-05-05
CN1349510A (zh) 2002-05-15
EP1171424B1 (de) 2009-05-27
HK1045513A1 (zh) 2002-11-29
CO5170500A1 (es) 2002-06-27
DE19918211A1 (de) 2000-10-26
ES2325674T3 (es) 2009-09-14
DE50015651D1 (de) 2009-07-09
CZ20013775A3 (cs) 2002-10-16
IL145882A0 (en) 2002-07-25
ZA200108204B (en) 2004-05-26
NZ514930A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
HUP0200859A2 (hu) Cikloalkil-szubsztituált benzimidazolok, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
HUP0301344A2 (hu) Nem szteroid gyulladásgátlók, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SV2003000162A (es) Los inhibidores triciclicos de poli (adp-ribosa) polimerasas
HUP0301269A2 (hu) Ftalazinonszármazékok és ezeket tartalmazó gyógyszerkészítmények
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
SG151250A1 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
HUP0203225A2 (hu) Benzodiazepinszármazékok, előállításuk és alkalmazásuk
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DK1678166T3 (da) Proteinkinaseinhibitorer
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
DE60101000D1 (de) N-heterocyclische derivate als nos inhibitoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
WO1999062909A3 (en) Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9901077D0 (sv) Novel use
RS50229B (sr) Analozi vitamina d3
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
ATE337827T1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
ATE11049T1 (de) Aktive pharmazeutische spirohydantoinderivate.
SE9904128D0 (sv) Novel compounds
HUP0401885A2 (hu) Új hidroxialkil-indolokarbazol-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
DK1246825T3 (da) Kondenserede pyrrolforbindelser, farmaceutiske midler indeholdende dem og anvendelse deraf